EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Bispecific antibody drug conjugates: Making 1+1>2

Yilin Gu, Zhijia Wang, Yuxi Wang

Acta Pharmaceutica Sinica B · 2024-05 · 14 (5) · 1965-1986

DOI: 10.1016/j.apsb.2024.01.009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2024-05. Verfasst von Yilin Gu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network,…. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 244 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Department of Sichuan Province, National Natural Science Foundation of China, Sichuan Provincial Science and Technology Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific antibody‒drug conjugates (BsADCs) represent an innovative therapeutic category amalgamating the merits of antibody‒drug conjugates (ADCs) and bispecific antibodies (BsAbs). Positioned as the next-generation ADC approach, BsADCs hold promise for ameliorating extant clinical challenges associated with ADCs, particularly pertaining to issues such as poor internalization, off-target toxicity, and drug resistance. Presently, ten BsADCs are undergoing clinical trials, and initial findings underscore the imperative for ongoing refinement. This review initially delves into specific design considerations for BsADCs, encompassing target selection, antibody formats, and the linker-payload complex. Subsequent sections delineate the extant progress and challenges encountered by BsADCs, illustrated through pertinent case studies. The amalgamation of BsAbs with ADCs offers a prospective solution to prevailing clinical limitations of ADCs. Nevertheless, the symbiotic interplay among BsAb, linker, and payload necessitates further optimizations and coordination beyond a simplistic "1 + 1" to effectively surmount the extant challenges facing the BsADC domain.

Schlagwörter

Stichwörter der Autor:innen

Antibody drug conjugatesBispecific antibodyBispecific antibody drug conjugatesEGFRHER2SafetyTargeted therapy

Autor:innen und Institutionen

  • Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, National Clinical Research Center for Geriatrics, West China Hospital…
  • Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu 610212, China.

Förderung

  • Science and Technology Department of Sichuan Province
  • National Natural Science Foundation of China
  • Sichuan Provincial Science and Technology Support Program

Zitieren

APA

Gu, Y., Wang, Z., & Wang, Y. (2024). Bispecific antibody drug conjugates: Making 1+1>2. Acta Pharmaceutica Sinica B, 14(5), 1965-1986. https://doi.org/10.1016/j.apsb.2024.01.009

Vancouver

Gu Y, Wang Z, Wang Y. Bispecific antibody drug conjugates: Making 1+1>2. Acta Pharmaceutica Sinica B. 2024;14(5):1965-1986. doi:10.1016/j.apsb.2024.01.009

BibTeX
@article{Gu2024,
  author = {Gu, Yilin and Wang, Zhijia and Wang, Yuxi},
  title = {Bispecific antibody drug conjugates: Making 1+1>2},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2024},
  volume = {14},
  number = {5},
  pages = {1965--1986},
  doi = {10.1016/j.apsb.2024.01.009}
}
Kostenlos starten →